Freising-weihenstephan
FREISING-WEIHENSTEPHAN, Germany, September 28, 2010 - Pieris AG (www.pieris-ag.com/) announced today the signature of a
collaboration and license agreement with both Sanofi-Aventis and Sanofi
Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and
NYSE: SNY), under which Pieris will apply its proprietary Anticalin
technology to discover novel Anticalin drugs against multiple targets, with
further development undertaken by Sanofi-Aventis and Sanofi-Pasteur.
FREISING-WEIHENSTEPHAN, Germany, June 15, 2010 - Pieris AG announced today the initiation of a Phase I clinical trial in
cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin.
FREISING-WEIHENSTEPHAN, Germany, June 7, 2010 - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the
company as Chief Scientific Officer, effective immediately.
FREISING-WEIHENSTEPHAN, Germany, April 30, 2010 - Pieris AG announced today preclinical data for its proprietary PRS-110
Anticalin(R) compound, which targets the c-Met receptor, demonstrating a
dose-dependant reduction of tumor growth in a xenograft mouse model.
FREISING-WEIHENSTEPHAN, Germany, January 4 - Pieris AG today announced the appointment of Stephen S.
